{
    "organizations": [],
    "uuid": "d58e7d88ab78d1ba67b77c80ff0e48ca14232d30",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astellas-pharma-says-application-o/brief-astellas-pharma-says-application-of-marketing-approval-for-blinatumomab-in-japan-idUSL4N1P41AH",
    "ord_in_thread": 0,
    "title": "BRIEF-Astellas Pharma says application of marketing approval for blinatumomab in Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 9 (Reuters) - Astellas Pharma Inc\n* Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTEÂ®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia\n* In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co\nSource text in Japanese: goo.gl/iGVamQ\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-09T09:36:00.000+02:00",
    "crawled": "2018-01-09T17:11:22.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "astellas",
        "pharma",
        "inc",
        "say",
        "announced",
        "application",
        "submitted",
        "japan",
        "marketing",
        "authorization",
        "bispecific",
        "cd3",
        "cell",
        "engager",
        "antibody",
        "construct",
        "blinatumomab",
        "treat",
        "relapsed",
        "refractory",
        "precursor",
        "acute",
        "lymphoblastic",
        "leukemia",
        "japan",
        "blinatumomab",
        "jointly",
        "developed",
        "amgen",
        "astellas",
        "biopharma",
        "co",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}